JP2021500903A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500903A5
JP2021500903A5 JP2020523976A JP2020523976A JP2021500903A5 JP 2021500903 A5 JP2021500903 A5 JP 2021500903A5 JP 2020523976 A JP2020523976 A JP 2020523976A JP 2020523976 A JP2020523976 A JP 2020523976A JP 2021500903 A5 JP2021500903 A5 JP 2021500903A5
Authority
JP
Japan
Prior art keywords
modified oligonucleotide
compound
nucleoside
seq
wing segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500903A (ja
JP7431728B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058354 external-priority patent/WO2019089692A1/en
Publication of JP2021500903A publication Critical patent/JP2021500903A/ja
Publication of JP2021500903A5 publication Critical patent/JP2021500903A5/ja
Priority to JP2023189307A priority Critical patent/JP2024023235A/ja
Application granted granted Critical
Publication of JP7431728B2 publication Critical patent/JP7431728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523976A 2017-10-31 2018-10-31 ENaC発現の調節因子 Active JP7431728B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023189307A JP2024023235A (ja) 2017-10-31 2023-11-06 ENaC発現の調節因子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762579640P 2017-10-31 2017-10-31
US62/579,640 2017-10-31
US201862743669P 2018-10-10 2018-10-10
US62/743,669 2018-10-10
PCT/US2018/058354 WO2019089692A1 (en) 2017-10-31 2018-10-31 MODULATORS OF ENaC EXPRESSION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023189307A Division JP2024023235A (ja) 2017-10-31 2023-11-06 ENaC発現の調節因子

Publications (3)

Publication Number Publication Date
JP2021500903A JP2021500903A (ja) 2021-01-14
JP2021500903A5 true JP2021500903A5 (cg-RX-API-DMAC7.html) 2021-12-09
JP7431728B2 JP7431728B2 (ja) 2024-02-15

Family

ID=66333370

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523976A Active JP7431728B2 (ja) 2017-10-31 2018-10-31 ENaC発現の調節因子
JP2023189307A Pending JP2024023235A (ja) 2017-10-31 2023-11-06 ENaC発現の調節因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023189307A Pending JP2024023235A (ja) 2017-10-31 2023-11-06 ENaC発現の調節因子

Country Status (16)

Country Link
US (2) US20210180057A1 (cg-RX-API-DMAC7.html)
EP (1) EP3703702A4 (cg-RX-API-DMAC7.html)
JP (2) JP7431728B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200079505A (cg-RX-API-DMAC7.html)
CN (1) CN111372594A (cg-RX-API-DMAC7.html)
AU (1) AU2018357932A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005038A2 (cg-RX-API-DMAC7.html)
CA (1) CA3074739A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000586A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020003134A2 (cg-RX-API-DMAC7.html)
IL (1) IL274231A (cg-RX-API-DMAC7.html)
MX (1) MX2020003554A (cg-RX-API-DMAC7.html)
PE (1) PE20200749A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202001863PA (cg-RX-API-DMAC7.html)
TW (1) TW201927313A (cg-RX-API-DMAC7.html)
WO (1) WO2019089692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3990119A4 (en) * 2019-06-26 2024-03-27 Fred Hutchinson Cancer Center METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATION THERAPIES FOR THE TREATMENT OF CANCERS AND RELATED DISORDERS
PL3956450T3 (pl) 2019-07-26 2025-12-22 Ionis Pharmaceuticals, Inc. Związki i sposoby modulowania gfap

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2304057B1 (en) * 2008-06-17 2014-09-17 Signature Diagnostics AG Method for the detection of ovarian cancer
US9574193B2 (en) * 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US10590485B2 (en) * 2014-05-29 2020-03-17 Geneticure Llc Therapeutic regimen for hypertension

Similar Documents

Publication Publication Date Title
JP2020193199A5 (cg-RX-API-DMAC7.html)
US20160201064A1 (en) Compositions and methods for modulating expression of frataxin
JP2015518710A (ja) ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
BR112017018383B1 (pt) Compostos anti-sentido que induzem a inclusão de éxon2, composições farmacêuticas que compreendem ditos compostos e usos dos mesmos para tratar doença de armazenamento de glicogênio tipo ii
JP2015518712A (ja) Mecp2発現を調節するための組成物及び方法
CN110832077B (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
JP2019529489A5 (cg-RX-API-DMAC7.html)
CN1247473A (zh) 治疗与呼吸失调和肺部炎症相关的疾病和症状的药剂和方法
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2011519579A (ja) 炎症および新生細胞増殖の治療のためのオリゴヌクレオチド
TW202304474A (zh) 用於抑制晚期糖化終產物之受體表現之RNAi藥劑、其組合物及使用方法
TW202130809A (zh) 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
CA2316994A1 (en) Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US20260043029A1 (en) RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use
CA2996164A1 (en) Modified antisense oligomers for exon inclusion in spinal muscular atrophy
JP2004532900A5 (cg-RX-API-DMAC7.html)
CA2451738A1 (en) Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine
TW202313068A (zh) 用於抑制黏蛋白5AC(MUC5AC)表現之RNAi藥劑、其組合物及使用方法
TW202345868A (zh) 用於抑制高度糖化終產物受體(RAGE)之表現的RNAi藥劑之皮下遞送
JP2024023235A5 (cg-RX-API-DMAC7.html)
CN101087623B (zh) 用于治疗变态反应和肿瘤细胞增殖的反义寡核苷酸
CN117440817A (zh) 用于抑制晚期糖基化终末产物受体表达的RNAi剂、其组合物和使用方法
KR20140014179A (ko) 키메라 벡본 및 2-아미노-2''-데옥시아데노신을 포함하는 올리고뉴클레오티드 저해제
AU2024364737A1 (en) Antisense oligonucleotides targeting rage
WO2025000059A1 (en) Compounds and uses therefor